论文部分内容阅读
目的通过观察替米沙坦对HepG2细胞和C2C12细胞过氧化物酶体激增剂激活受体(PPAR)α和脂蛋白脂肪酶(LPL)表达的影响,以探讨其改善脂肪酸代谢的机制。方法在HepG2细胞和诱导成熟后的C2C12细胞中加入不同浓度的替米沙坦培养48h以及同一浓度替米沙坦作用的不同时间,应用RT-PCR方法检测PPAR-α和LPLmRNA的表达,用Western blot杂交法检测PPARα和LPL蛋白的表达。然后在HepG2细胞血用PPARα选择性拮抗剂MK886阻断替米沙坦作用,24h后观察LPLmRNA的表达。结果 (1)替米沙坦呈剂量和时间依赖性增强HepG2细胞中PPARα和LPLmRNA和其蛋白质的表达,但对C2C12中PPARα和LPL的表达无明显影响。(2)替米沙坦对HepG2细胞中LPLmRNA的上调作用可以被MK886抑制。结论替米沙坦在人类肝脏细胞中可以同时上调PPARα和LPL的表达,并且对LPL的调节作用是通过PPARα介导的。
Objective To investigate the effect of telmisartan on the expression of peroxisome proliferator-activated receptor (PPAR α) and lipoprotein lipase (LPL) in HepG2 cells and C2C12 cells to explore the mechanism of its effect on improving fatty acid metabolism. Methods The expression of PPAR-α and LPL mRNA in HepG2 cells and C2C12 cells induced by different concentrations of telmisartan for 48 h and the same concentration of telmisartan were detected by RT-PCR. blot hybridization was used to detect the expression of PPARα and LPL protein. Then, the effect of telmisartan was blocked by PPARα selective antagonist MK886 in HepG2 cells, and the expression of LPL mRNA was observed 24h later. Results (1) Telmisartan increased the expression of PPARα and LPL mRNA and protein in HepG2 cells in a dose- and time-dependent manner, but did not affect the expression of PPARα and LPL in C2C12 cells. (2) Telmisartan upregulation of LPL mRNA in HepG2 cells can be inhibited by MK886. Conclusion Telmisartan can up-regulate the expression of PPARα and LPL in human liver cells simultaneously, and the regulatory effect on LPL is mediated by PPARα.